Inhibitors of Bruton tyrosine kinase (Btk) have been proposed as novel antiplatelet agents. In this study we show that low concentrations of the Btk inhibitor ibrutinib block CLEC-2-mediated activation and tyrosine phosphorylation including Syk and PLCγ₂ in human platelets. Activation is also blocked in patients with X-linked agammaglobulinaemia (XLA) caused by a deficiency or absence of Btk. In contrast, the response to GPVI is delayed in the presence of low concentrations of ibrutinib or in patients with XLA, and tyrosine phosphorylation of Syk is preserved. A similar set of results is seen with the second-generation inhibitor, acalabrutinib. The differential effect of Btk inhibition in CLEC-2 relative to GPVI signaling is explained by the positive feedback role involving Btk itself, as well as ADP- and thromboxane A₂-mediated activation of P2Y₁₂ and TP receptors, respectively. This feedback role is not seen in mouse platelets and, consistent with this, CLEC-2-mediated activation is blocked by high but not by low concentrations of ibrutinib. Nevertheless, thrombosis was absent in eight out of 13 mice treated with ibrutinib. These results show that Btk inhibitors selectively block activation of human platelets by CLEC-2 relative to GPVI suggesting that they can be used at low doses in patients to target CLEC-2 in thrombo-inflammatory disease.
GTP exchange proteins and the effector protein, PLCγ2. This hemITAM signaling pathway is similar to that used by the ζζ-chain-containing platelet ITAM receptors such as the collagen receptor GPVI-FcγRII complex and the low affinity immune receptor FcγRIIA. A fundamental difference between these pathways is, however, that Syk binds to two phosphorylated tyrosines within a single ITAM in GPVI-FcγRII and FcγRIIA, and to two phosphorylated hemITAM in separate cytosolic receptor chains of CLEC-2. Another difference between CLEC-2 and GPVI signaling in human platelets is the critical dependence of CLEC-2 on positive feedback signaling through ADP and thromboxane A. (TXA), actin polymerization, and the small GTPase Rac. In contrast, these positive feedback pathways play a relatively minor role in CLEC-2 signaling in mouse platelets.

Recently, irreversible inhibitors of the Tec kinase Btk have entered clinical use for the treatment of B-cell malignancies. These include the first-generation inhibitor ibrutinib and the second-generation inhibitor acalabrutinib. Ibrutinib is associated with a significant increase in major bleeding which is much reduced with the second-generation inhibitor acalabrutinib. Patients with X-linked agammaglobulinemia (XLA) who have function-disrupting mutations or loss of Btk do not, however, have increased bleeding. This observation, coupled with protein biochemistry measurements, has led us to conclude that the bleeding induced by ibrutinib is due to the high-dosing strategy and off-target effects. Platelets express two members of the Tec family of tyrosine kinases, namely Btk and Tec. Btk has an approximate 10- to 20-fold greater level of expression in both human and mouse platelets. Various studies have shown redundancy between the two kinases downstream of GPVI, with Tec able to partially compensate for the absence of Btk in human platelets from patients with XLA and in mouse platelets, which are deficient in Btk.

Recently, Btk inhibitors have been proposed to represent a new class of antithrombotic drug based on the observation that they delay or inhibit ex vivo platelet activation by GPVI and by immobilized atherosclerotic plaque at arterial rates of flow. In addition, Btk inhibitors block platelet activation by CLEC-2. However, based on studies using ibrutinib-treated human platelets, Manne et al. have proposed that Btk, in contrast to GPVI, lies upstream of Syk in the CLEC-2 signaling cascade.

In the present study, we demonstrate that the results of Manne et al. are explained by the positive feedback role of ADP and TxA and that concentrations of ibrutinib that have little or no effect on the response to GPVI stimulation selectively block activation by CLEC-2. This observation, together with the pivotal role of CLEC-2 in thrombo-inflammation, suggests that inhibitors of Btk represent new antiplatelet agents for thrombo-inflammatory disorders with minimal effect on hemostasis.

**Methods**

**Platelet preparation**

Blood was obtained by centrifugation. Washed human and mouse platelets were obtained by further centrifugation of the platelet-rich plasma in the presence of prostacyclin and resuspended in modified Tyrode buffer as previously described. Platelets were used at a cell density of 4x10^9/ml for aggregometry and biochemical studies.

**Light transmission aggregometry**

Aggregation was monitored by light transmission using a Model 700 aggregometer (Chronolog, Havertown, PA, USA) as previously described.

**Protein phosphorylation**

Eptifibatide-treated, washed platelets were stimulated in a Model 700 aggregometer in the presence of ibrutinib or vehicle as described previously. Activation was terminated after 300 seconds by addition of reducing sample buffer. This was followed by lysisate separation by sodium dodecylsulfate polyacrylamide gel electrophoresis, electro-transfer and western blot as described previously.

**Inferior vena cava stenosis assay**

All mouse experiments were performed using wild-type (WT) mice on a C57Bl/6 genetic background under Home Office project licenses P0E9BD13 and PC427E5DD. Mice were sourced from Charles River UK Ltd. (Margate, UK). For ex vivo platelet function assays and in vivo thrombosis assays 8-week-old C57Bl/6 WT male mice were treated by intraperitoneal injection with a total dose of 140 mg/kg of ibrutinib or vehicle (5% dimethylsulfoxide, 30% polyethylene glycol 300, 5% Tween 20, 60% deionized water) in divided doses once daily over 2 – 4 days. Blood was taken at the stated times and platelet function analysis was performed as described above using flow cytometry.

The IVC stenosis model was performed as described by Payne et al. In brief, mice were anesthetized using isoflurane and then a laparotomy was performed. Side branches of the IVC were identified and tied off before the IVC itself was stenosed with a liguature and a 30-gauge spacer to maintain a small degree of vessel patency. The incision was then closed and mice were allowed to recover from surgery. Buprenorphine was used pre- and post-operatively for analgesia. Mice were then culled 48 h after the surgery and the IVC was examined for the presence and size of thrombus.

**Other methods**

Details of reagents and methods used for flow cytometry, flow adhesion, imaging, image analysis and cell transfection are detailed in the Online Supplementary Material.

**Statistical analysis**

All data are presented as mean ± standard error of the mean with statistical significance taken as P<0.05 unless otherwise stated. Statistical analyses were performed using the Mann-Whitney test, Fisher exact test, Welch t-test or one or two-way analysis of variance (ANOVA) with corrections for multiple comparisons, as stated. Statistical analysis of the half maximal inhibitory concentration (IC₅₀) values was performed using the Welch t-test. All statistical analyses were performed using GraphPad Prism 7 (GraphPad Software Inc. La Jolla, CA, USA).

**Ethical approval**

Ethical approval for collecting blood from patients and healthy volunteers was granted by the National Research Ethics Service (10/H1206/58) and Birmingham University Internal Ethical Committee.
Ethical Review (ERN_11-0175), respectively. Work on patients with XLA has ethical approval via the University of Birmingham Human Biomaterials Resource Centre (16-251 Amendment 3).

Results

**CLEC-2-mediated human platelet aggregation is inhibited by low concentrations of Btk inhibitors**

To examine the role of Btk downstream of platelet CLEC-2 in humans we took washed platelets from healthy donors and added increasing concentrations of ibrutinib before stimulating the platelets with the CLEC-2 agonist rhodocytin. As shown in Figure 1A, B, ibrutinib completely inhibited CLEC-2-mediated aggregation at concentrations as low as 70 nM. Inhibition was marked after 5 min incubation with ibrutinib and only increased slightly with times up to 60 min (Figure 1A, B and Online Supplementary Figure S1). Strikingly, the IC₅₀ for inhibition was over 20-fold lower than that required to block GPVI-mediated platelet aggregation¹⁶ (Table 1). This selective inhibition of the response to CLEC-2 activation is consistent with the results of Manne et al.²⁶

We further studied the effect of in vivo Btk inhibition on platelet-rich plasma obtained from patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib or the more specific second-generation Btk inhibitor acalabrutinib. Unlike platelets from patients treated with a control chemotherapy regimen (fludarabine, cyclophosphamide and rituximab; FCR), platelets from Btk inhibitor-treated patients did not aggregate even at high levels of CLEC-2 stimulation (Figure 1C). We have previously shown that platelet-rich plasma from Btk inhibitor-treated patients does, however, aggregate in response to GPVI and G protein-coupled receptor (GPCR) stimulation.¹⁵

**Adhesion to podoplanin under venous flow conditions is abrogated by Btk inhibition**

Given the role of platelet CLEC-2 and podoplanin in the thrombo-inflammatory and venous thrombosis models used by Hitchcock et al.⁴ and Payne et al.⁴ we investigated whether inhibition of CLEC-2-mediated platelet function...
by ibrutinib reduced or prevented adhesion to the endogenous ligand under flow. Blood from healthy donors, patients with XLA or those taking ibrutinib or acalabrutinib was flowed over podoplanin at a venous shear. Strikingly we found that both the adhesion and aggregate size of these platelets were markedly reduced when compared to those of platelets from healthy donor blood regardless of the method of Btk inhibition (Figure 2).

**Btk and Syk inhibition block CLEC-2-mediated Btk phosphorylation**

To examine the effect of ibrutinib on CLEC-2-mediated protein phosphorylation, ibrutinib-treated washed human platelets were lysed after stimulation with rhodocytin and lysates probed with phosphospecific antibodies. As shown in Figure 3A, phosphorylation of Syk Y525/6, LAT Y200, Btk Y223 and Y551, and PLCγ2 Y1217 was blocked by 70 nM ibrutinib with IC₅₀ values similar to those for aggregation (Table 1). This concentration of ibrutinib reduced total phosphotyrosine to basal levels and inhibited phosphorylation on all measured tyrosine sites except the constitutive phosphorylation of Src Y418. Loss of Src pY418 was seen at higher concentrations of ibrutinib (Figure 3Aiv) as in our previous study.⁶

We performed similar experiments with acalabrutinib and found that Btk Y223 phosphorylation was lost at a concentration (3 μM) that also partially inhibited phosphorylation of Syk (Online Supplementary Figure S2). This concentration caused a marked reduction in platelet activation by CLEC-2 but no change in platelet aggregation in response to GPVI ligation,⁶ confirming the selectivity for CLEC-2. The observation, however, of partial phosphorylation of Syk and complete abrogation of phosphorylation of Btk in the presence of acalabrutinib suggests that Btk does not lie upstream of Syk, in contrast to the conclusion of Manne et al.⁶

A further prediction in the model of Manne et al., in which Syk lies downstream of Btk, is that inhibition of Syk should not block phosphorylation of Btk. To test this, we incubated human platelets with increasing concentrations of the Syk inhibitor PRT 060318 prior to stimulation with rhodocytin. Lysates were then probed using phosphospecific antibodies to Syk pY525/6, LAT pY200, Btk pY551 and PLCγ2 pY1217. *Online Supplementary Figure S3* shows that phosphorylation of Syk, LAT, Btk and PLCγ2 were lost in tandem, providing further evidence against the model. This result is in keeping with our previous results examining CLEC-2-mediated phosphorylation events in mice with a Syk mutation rendering it unable to undergo tyrosine phosphorylation.¹

In summary, the above results show that low concentrations of ibrutinib and acalabrutinib selectively block platelet activation by CLEC-2 over GPVI and provide evidence against the model of Manne et al. in which Btk lies upstream of Syk.

**ADP rescues Syk phosphorylation in the presence of Btk inhibition**

We have previously shown that CLEC-2 signaling in human platelets is critically dependent on positive feedback signals from thromboxane TP and ADP P2Y₂ receptors.⁸ Our standard platelet preparation method leads to partial desensitization of the ADP P2Y₂ receptor⁹ and loss of aggregation in response to ADP as a consequence of this (Online Supplementary Figure S4). This may have accentuated the previously described dependency on P2Y₂ receptors. To investigate this, we repeated the studies on aggregation and protein phosphorylation but in the presence of excess ADP (10 μM). Similar to the results with no added ADP, 70 nM ibrutinib inhibited aggregation (Figure 3Bii) and phosphorylation of Btk Y223 and PLCγ2 Y1217 (Figure 3B-ii). In contrast, however, it did not inhibit phosphorylation of Syk Y525/6, LAT Y200 or Btk on its Src kinase phosphorylation site Y551 (Figure 3Bii and iii). The demonstration of phosphorylation of Syk, LAT and Btk on Y551 but absence of Btk autophosphorylation on Y223 in ibrutinib-treated human platelets confirms that Btk lies downstream of Syk in the CLEC-2 signaling cascade in human platelets.

**CLEC-2-mediated platelet aggregation and tyrosine phosphorylation are blocked in patients with Btk mutations**

Our previous study found off-target effects of ibrutinib even when used at concentrations as low as 70 nM.¹⁰ To investigate whether the potent inhibition of CLEC-2-mediated platelet activation by ibrutinib was mediated by its blockade of Btk or an off-target effect, we studied platelet aggregation in response to rhodocytin in patients with XLA. CLEC-2-mediated aggregation and phosphorylation of PLCγ2 Y1217 were blocked, whereas phosphorylation of Syk Y525/6 and LAT Y200 was only partially reduced (Figure 4). These findings demonstrate that the initial phosphorylation of Syk and LAT is independent of Btk and that this is then increased by a Btk-dependent pathway.

---

**Table 1. Half maximal inhibitory concentration (IC₅₀) values for all dose-response curves shown in the figures in this publication.**

<table>
<thead>
<tr>
<th>Figure</th>
<th>Dose-response curve</th>
<th>IC₅₀ (μM)</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>1B</td>
<td>HD Aggregation</td>
<td>0.023</td>
<td>0.009 – 0.053</td>
</tr>
<tr>
<td>3Aii</td>
<td>HD Btk pY223</td>
<td>0.024</td>
<td>0.002 – 0.133</td>
</tr>
<tr>
<td>3Aiii</td>
<td>HD PLCγ2 pY1217</td>
<td>0.034</td>
<td>0.010 – 0.119</td>
</tr>
<tr>
<td>3Aiii</td>
<td>HD Syk pY525/6</td>
<td>0.052</td>
<td>0.020 – 0.150</td>
</tr>
<tr>
<td>3Aiii</td>
<td>HD LAT pY200</td>
<td>0.036</td>
<td>0.023 – 0.189</td>
</tr>
<tr>
<td>3Aiii</td>
<td>HD SLP76 pY145</td>
<td>0.032</td>
<td>0.015 – 0.066</td>
</tr>
<tr>
<td>3Aiii</td>
<td>HD Btk pY551</td>
<td>0.059</td>
<td>0.023 – 0.179</td>
</tr>
<tr>
<td>3Aiv</td>
<td>HD Src pY418</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>3Bii</td>
<td>HD Aggregation (added 10 μM ADP)</td>
<td>0.034</td>
<td>0.017 – 0.07</td>
</tr>
<tr>
<td>3Bii</td>
<td>HD Btk pY223 (added 10 μM ADP)</td>
<td>0.006</td>
<td>0.003 – 0.009</td>
</tr>
<tr>
<td>3Bii</td>
<td>HD PLCγ2 pY1217 (added 10 μM ADP)</td>
<td>0.023</td>
<td>0.014 – 0.037</td>
</tr>
<tr>
<td>6B</td>
<td>WT Mouse WP Aggregation</td>
<td>13.28</td>
<td>4.650 – 129.2</td>
</tr>
<tr>
<td>6Bii</td>
<td>WT Mouse Btk pY223</td>
<td>0.076</td>
<td>0.011 – 0.559</td>
</tr>
<tr>
<td>6Bii</td>
<td>WT Mouse PLCγ2 pY53</td>
<td>0.074</td>
<td>0.026 – 0.200</td>
</tr>
<tr>
<td>6Bii</td>
<td>WT Mouse PLCγ2 pY59</td>
<td>0.065</td>
<td>0.017 – 0.232</td>
</tr>
<tr>
<td>6Bii</td>
<td>WT Mouse PLCγ2 Y1217</td>
<td>0.122</td>
<td>0.044 – 0.363</td>
</tr>
<tr>
<td>6Bii</td>
<td>WT Mouse Syk pY525/6</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>6Bii</td>
<td>WT Mouse LAT pY132</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>6Bii</td>
<td>WT Mouse LAT pY200</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>6Bii</td>
<td>WT Mouse Btk pY551</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>6Biv</td>
<td>WT Mouse Src pY418</td>
<td>0.35</td>
<td>0.126 – 1.036</td>
</tr>
</tbody>
</table>

Where no value is shown this indicates that the IC₅₀ could not be calculated. 95% CI: 95% confidence interval. HD: healthy donor. WT: wild-type.
Figure 2. Btk inhibition blocks platelet adhesion to podoplanin under venous flow conditions. (A, B) Whole blood from healthy donors, patients treated with ibrutinib or acalabrutinib or those with X-linked agammaglobulinemia (XLA) was incubated with DiOC dye for 5 min before being flowed across a capillary coated with podoplanin-Fc (100 μg/mL) at 125 s⁻¹ for 5 min. Images were taken every second using fluorescent channels on a Zeiss Axio inverted microscope at 20X magnification. Representative images from healthy donors (Ai), patients treated with ibrutinib 420 mg once daily (Aii), patients treated with acalabrutinib 100 mg twice daily (Bi) or patients with XLA (Bii). Ilastik 1.1.2 machine learning software was used to automatically and reproducibly identify platelets. Data on platelet surface area coverage and cluster size were measured using the KNIME 3.4 analytics platform. (C, D) Mean ± standard error of mean (SEM) showing the increases in total platelet aggregate area over time of healthy donors (n=4) and ibrutinib-treated patients (n=5) (C) and in acalabrutinib-treated patients (n=2) and patients with XLA (n=2) (D). (E,F) Mean ± SEM showing increases in mean aggregate size over time of healthy donors and ibrutinib-treated patients (E) and of acalabrutinib-treated patients and patients with XLA, with the curve from healthy donor platelets included for comparison (F). The statistical analysis was performed with two-way analysis of variance. *P<0.05, ns=not significant.
Figure 3. Low concentrations of ibrutinib block all phosphorylation events downstream of platelet CLEC-2 ligation. Blockade upstream of Btk pY223 is rescued by addition of excess ADP. (A, B) Healthy donor washed human platelets at 4x10^8/mL were incubated in the presence of eptifibatide 9 mM with ibrutinib or vehicle for 5 min without (A) or with (B) ADP at 10 μM prior to stimulation with 300 nM rhodocytin. Platelets were then lysed with 5X reducing sample buffer 5 min after addition of agonist. Whole cell lysates were then separated by sodium dodecylsulfate polyacrylamide gel electrophoresis and western blots were probed for whole cell phosphorylation or kinase phosphorylation with the stated antibodies downstream of the platelet CLEC-2 receptor. A representative blot from four identical experiments (i). Mean tyrosine phosphorylation levels ± standard error of mean (SEM) of four identical experiments for phosphorylation events downstream (ii) and upstream (iii) of Btk pY223 as well as Src pY418 (iv). The mean aggregation trace from Figure 1B is included as a dotted line to aid comparison. Mean ± SEM of three identical experiments for light transmission aggregometry measurements in the presence of ADP 5 min after stimulation with 300 nM rhodocytin are shown as a solid line in (ii) and as a dotted line in (iii). Rho: rhodocytin.
The kinase domain of Btk is required for signaling downstream of CLEC-2

We have previously shown that Btk supports platelet activation by GPVI through acting both as a kinase and as an adapter protein. However, the observation of complete loss of aggregation in the presence of ibrutinib and acalabrutinib suggests that the kinase activity of Btk is critical for activation by CLEC-2. Consistent with this, wild-type but not kinase-dead Btk restored NFAT signaling in a CLEC-2-transfected cell line model, which was blocked by ibrutinib and acalabrutinib (Figure 5A-C). CLEC-2 and Btk expression was similar regardless of the Btk construct used (Figure 5D, E). The lack of signaling with kinase-dead Btk confirms a fundamental difference between the role of Btk in the CLEC-2 and GPVI signaling pathways.

Btk does not lie upstream of Syk in CLEC-2-stimulated mouse platelets

We extended the studies to investigate the role of Btk in CLEC-2 signaling in mouse platelets. In agreement with the results of Lee et al., we found that only high concentrations of ibrutinib, which abrogated platelet activation by GPVI, blocked CLEC-2-mediated platelet aggregation (Figure 6A, Table 1 and data not shown). Phosphorylation of Syk Y519/520 (equivalent to Y525/526 in human platelets), and LAT Y132 and Y200 was preserved in the presence of ibrutinib (Figure 6B). This is consistent with the results in human platelets stimulated by CLEC-2 in the presence of ADP and further confirms that Btk does not lie upstream of Syk and LAT in mouse platelets.

The effect of ibrutinib on deep vein thrombosis

We sought to establish whether ibrutinib would prevent IVC thrombus formation in a mouse model of deep vein thrombosis (DVT) that is known to be dependent on CLEC-2. Mice were dosed with ibrutinib via intraperitoneal injection for up to 4 days. This dosing strategy blocked CLEC-2-mediated but not PAR4-mediated platelet activation (Figure 7A). Mice dosed with ibrutinib had a reduction in thrombus prevalence relative to controls (Figure 7Bi) but this was not statistically significant. In the small number of ibrutinib-treated mice which still formed IVC thrombi, thrombus size was not significantly altered relative to that in controls (Figure 7Bii).
Discussion

The main findings from the above studies into the role of Btk downstream of CLEC-2 receptor ligation in platelets are: (i) Btk lies downstream of Syk in the CLEC-2 signaling cascade in human and mouse platelets, in contrast to the conclusion of Manne et al.; and (ii) Btk inhibitors selectively block platelet activation by CLEC-2 relatively to GPVI. This suggests that Btk inhibitors can be used to selectively block CLEC-2-mediated platelet activation in thrombo-inflammation without any increase in bleeding or other side effects due to blockade of GPVI and ITAM receptors in other cells.

The results described here do not support the conclusions of Manne et al. that Btk lies upstream of Syk in CLEC-2 signaling in both human and mouse platelets. While we were able to replicate the complete loss of whole cell tyrosine, Syk and Btk phosphorylation with ibrutinib in human platelets reported by Manne et al., we show that ibrutinib blocks Btk phosphorylation at its Src phosphorylation site (Y551) which is not in keeping with the known mechanism of action of ibrutinib: Btk is phosphorylated by Src at Y551 but ibrutinib then blocks subsequent autophosphorylation at Y223. We also report loss of Btk phosphorylation using the Syk inhibitor PRT 060318. Both of these findings are inconsistent with a model in which Btk lies upstream of Syk. This is further supported by the observation that phosphorylation of Syk and Btk Y551 is restored in the presence of the secondary messenger ADP. These results demonstrate that the phosphorylation of Syk is initially independent of Btk and is then increased by a pathway that involves Btk and ADP.

Our results show that human CLEC-2-mediated platelet activation is critically dependent on the kinase function of Btk. Platelets exposed to low concentrations of ibrutinib and the more Btk-selective acalabrutinib, as well as platelets from patients treated with these inhibitors and patients with genetic loss-of-function mutations of Btk, do
Figure 6. Ibrutinib blocks CLEC-2-mediated tyrosine phosphorylation of Btk pY223 at low concentrations in mouse platelets. Aggregation is only blocked at ~250-fold higher concentrations. (A) Wild-type mouse washed platelets at 4x10^8/mL were incubated with vehicle or ibrutinib for 5 min prior to stimulation with rhodocytin 300 nM for 5 min. A representative light transmission aggregometry trace from three identical experiments is shown. (B) Eptifibatide (9 μM)-treated wild-type mouse washed platelets at 4x10^8/mL were incubated with ibrutinib or vehicle for 5 min before being stimulated with rhodocytin 300 nM. Platelets were then lysed with 5X reducing sample buffer 5 min after addition of an agonist. Whole cell lysates were then separated by sodium dodecylsulfate polyacrylamide gel electrophoresis and western blots were probed for whole cell phosphorylation or kinase phosphorylation with the stated antibodies downstream of the platelet CLEC-2 receptor. (i) Representative blots and (ii-iv) mean results of three identical experiments examining degree of aggregation and tyrosine phosphorylation levels of the proteins shown. Mean aggregation (n=3) results are shown in (ii) and are included as dotted lines in (iii-iv) to aid comparison. All results are shown as mean ± standard error of mean. OD: optical density.
Figure 7. Mice dosed with ibrutinib have a trend towards reduction of thrombus formation in an in vivo venous thrombosis model. Wild-type mice were dosed with ibrutinib (35–70 mg/kg) or vehicle for 1–3 days before and 2 days following inferior vena cava (IVC) stenosis surgery to achieve consistent CLEC-2 inhibition throughout the post-surgical period. (A) Heparinized whole blood was collected via tail bleeding from mice undergoing the same dosing schedule but not undergoing surgery at the stated time points. The blood was incubated with FITC-conjugated anti-P-selectin and PE-conjugated anti-activated integrin αIIbβ3 antibodies for 30 min before undergoing red cell lysis and fixation and analysis using flow cytometry. The effect on platelet activation after stimulation with PAR4 peptide (500 nM) and rhodocytin (300 nM) is shown as (i) representative plots, (ii) mean data ± standard error of mean (ibrutinib, n=6; vehicle, n=3). (B) Two hours following the pre-surgical dose of ibrutinib or vehicle, IVC stenosis was induced under general anesthesia with a ligature. Mice were allowed to recover and were then culled 48 h later and examined for the size of any IVC thrombus. (i) Thrombus prevalence and (ii) thrombus weight are shown (ibrutinib, n=13; vehicle, n=12). The horizontal line represents the median thrombus weight. A Fisher exact test was used for the statistical analysis of thrombus prevalence, whereas a Mann-Whitney test was used for the analysis of weight. ns=not significant. SSC: side scatter; FSC: forward scatter.
not demonstrate any CLEC-2-mediated activation, even when stimulated with very high levels of agonist. We have previously shown that genetic or pharmacological Btk inhibition of platelets does not result in loss of activation in response to GPVI in human platelets because: (i) Btk was able to function as an adapter downstream of GPVI to preserve platelet activation; and (ii) Tec may be able to compensate for the lack of Btk kinase or adapter activity. Here we show that Tec is not able to compensate for a lack of Btk in the CLEC-2 signaling cascade through studies on patients with XLA and that the kinase domain of Btk is critical for CLEC-2 signaling in a transduced cell line model.

The present results suggest that Btk inhibitors have the potential to be used at very low concentrations as selective inhibitors of CLEC-2 in thrombo-inflammatory disorders with minimal off-target effects and no increased bleeding. Not only does Btk inhibition prevent platelet activation in response to CLEC-2 but we have shown that it also results in abrogation of platelet adhesion to podoplanin at venous rates of shear and a reduction in DVT formation in ibritumomab-treated mice. The in vivo DVT study was powered based on the rates of thrombosis seen in CLEC-2-deficient and WT mice in the studies by Payne et al. The lack of statistical significance in the trend towards inhibition of DVT formation may reflect the fact that pharmacological blockade of Btk in mice did not result in full inhibition of CLEC-2 signaling throughout the 48 h required for venous thrombosis in this model and the fact that, unlike for human CLEC-2 signaling, mouse CLEC-2 is not critically dependent on Btk. Interestingly the thrombi that did form in the ibritumomab-treated mice were the same size as those in the control mice. This is consistent with a model in which CLEC-2 activation is required to initiate formation of a thrombus, but not its propagation.

In conclusion, the present study shows that Btk lies downstream of Syk in human and mouse platelets and that Btk inhibitors block human CLEC-2-mediated platelet function at concentrations more than 20-fold lower than those that block GPVI signaling and mouse CLEC-2. The mechanism underlying this selectivity is that Btk kinase activity is critical for human platelet CLEC-2 function, but not for GPVI. This means that lower dose Btk inhibitors could be used therapeutically to inhibit CLEC-2 in platelets without any off-target effects on GPVI and ITAM receptors in other hematopoietic cells. This provides a mechanism for selective targeting of CLEC-2 in thrombo-inflammatory disorders, such as DVT or infection-driven thrombosis, while preserving hemostasis.1,4

Disclosures
This work was supported by British Heart Foundation (BHF) Programme grant (RG/15/18/30563), a BHF Clinical Fellowship to PLRN (FS/17/20/52738), a BHF Senior Basic Science Research Fellowship to AB (FS/19/50/54173), an AMS springboard grant to AYP (SBF0021699) and the University of Birmingham’s Institute of Translation Medicine and Institute of Cardiovascular Sciences; SPW holds a BHF Chair (CH03/003). JAE is supported by the Deutsche Forschungsgemeinschaft (DFG grant: Eh1777/13-1). Btk deficient DT40 cells, plasmid constructs and rabbit anti-Btk antibody were a kind gift from Dr Mike Tomlinson (University of Birmingham, UK). P.L.R Nicolson has received research grants from Janssen Pharmaceuticals, Novartis Pharmaceuticals and materials from Principia Biopharma.

Contributions
PLRN, CEH, SHN and SPW conceived the study and wrote the manuscript. PLRN, SHN, JH, LG-Q, CWS, JC, AB, AOK, NSP, D NK, SW and CNW performed experiments. PLRN, SHN, JH and JAP performed data analysis. HC and APH consented and provided access to patients with XLA. JAE provided key reagents. GP consented and provided access to patients with CLL, CEH, AYP and SPW supervised the study. All authors critically appraised the manuscript.

Acknowledgments
This work was supported by a British Heart Foundation (BHF) Programme grant (RG/15/18/30563), a BHF Clinical Fellowship to PLRN (FS/17/20/52738), a BHF Senior Basic Science Research Fellowship to AB (FS/19/50/54173), an AMS springboard grant to AYP (SBF0021699) and the University of Birmingham’s Institute of Translation Medicine and Institute of Cardiovascular Sciences; SPW holds a BHF Chair (CH03/003). JAE is supported by the Deutsche Forschungsgemeinschaft (DFG grant: Eh1777/13-1).

References

Disclosures
This work was supported by British Heart Foundation (BHF) Programme grant (RG/15/18/30563), a BHF Clinical Fellowship to PLRN (FS/17/20/52738), a BHF Senior Basic Science Research Fellowship to AB (FS/19/50/54173), an AMS springboard grant to AYP (SBF0021699) and the University of Birmingham’s Institute of Translation Medicine and Institute of Cardiovascular Sciences; SPW holds a BHF Chair (CH03/003). JAE is supported by the Deutsche Forschungsgemeinschaft (DFG grant: Eh1777/13-1). Btk deficient DT40 cells, plasmid constructs and rabbit anti-Btk antibody were a kind gift from Dr Mike Tomlinson (University of Birmingham, UK). P.L.R Nicolson has received research grants from Janssen Pharmaceuticals, Novartis Pharmaceuticals and materials from Principia Biopharma.

Contributions
PLRN, CEH, SHN and SPW conceived the study and wrote the manuscript. PLRN, SHN, JH, LG-Q, CWS, JC, AB, AOK, NSP, D NK, SW and CNW performed experiments. PLRN, SHN, JH and JAP performed data analysis. HC and APH consented and provided access to patients with XLA. JAE provided key reagents. GP consented and provided access to patients with CLL, CEH, AYP and SPW supervised the study. All authors critically appraised the manuscript.

Acknowledgments
This work was supported by a British Heart Foundation (BHF) Programme grant (RG/15/18/30563), a BHF Clinical Fellowship to PLRN (FS/17/20/52738), a BHF Senior Basic Science Research Fellowship to AB (FS/19/50/54173), an AMS springboard grant to AYP (SBF0021699) and the University of Birmingham’s Institute of Translation Medicine and Institute of Cardiovascular Sciences; SPW holds a BHF Chair (CH03/003). JAE is supported by the Deutsche Forschungsgemeinschaft (DFG grant: Eh1777/13-1).


